Leaders in Pharmaceutical Business Intelligence (LPBI) Group

9:30 – 10:00, 6/13/2014, David Bartel “MicroRNAs, poly(A) tails and post-transcriptional gene regulation”

Live from the Koch Symposium

Reporter: Aviva Lev-Ari, PhD, RN

Key concepts captured:

• MicroRNA miRNA – 4-5 conserved targets per miRNA family
• non-conserves targets are also important
• mechanism of miRNA -directed regulation
• Poly(A) tail promotes initiation, inhibits mRNA decay – what is the influence of tail extension – increase protein production
• Poly(A)-tail length can influence translational efficiency
• Poly(A)-tail length profiling
• Tail-length distribution for different genes graphed done by cell lines, embryonic cells when it broaden
• Tail-length conservation: length (half life) and stability (steady state)
• Regulations between de-adenylations rate and stability
• Ribosome Profiling: ribosome protected mRNA fragments (RPF)s
• Tail length and Translational efficiency – Relationships found and scatter graphed
• Developmental shift in the nature of translational control followed by transition in translational control
• mRNA – maternally inherited, Translation Coupled to poly(A) tail length, no transcription, limited utility of differential mRNA stability, Robust cytoplasmic poly-adenylation, tail length & translation coupled
• molecular consequences of miRNA targeting – Ribosome profiling, decrease in translational efficiency detected as a result of decreased in mRNA
• dynamics of regulation: protein translation – mRNA easier to detected than changes in protein level
• miRNA-mediated repression in the zebrafish embryo
• Risosome and mRNA changes after injecting miR-155 (RPF fold change vs RNA fold change) – 4hrs vs 6hrs – translational repression vs miRNA de-stabilization

9:30 – 10:00, 6/13/2014, David Bartel  “MicroRNAs, poly(A) tails and post-transcriptional gene regulation.”

@MIT – Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014 8:30AM – 4:30PM, Kresge Auditorium @MIT

http://ki.mit.edu/news/symposium

REALTIME event coverage for the Scientific Media by Dr.  A. Lev-Ari 

in Open Access Scientific Journal of Leaders in Pharmaceutical Business Intelligence (LPBI)

http://pharmaceuticalintelligence.com

  #pharmaIT,#BIOIT,#technews,#curation,#pharmanews,#mobilehealth,#mhealth,#science,#science2_0,#healtcare,#BIOIT14,#Boston ,@Biotech News,@MhealthForAll,@mHealthAlliance,@HCtrends,@mobilehealth360,@science 2_0

David Bartel, PhD 
Member, Whitehead Institute
Professor of Biology, Massachusetts Institute of Technology 
Investigator, Howard Hughes Medical Institute

David Bartel received his PhD from Harvard in 1993 and has since headed a lab at the Whitehead Institute for Biomedical Research, where he is also an Investigator of the Howard Hughes Medical Institute and a Professor of Biology at MIT. His lab initially studied the ability of RNA to catalyze reactions and more recently has focused on microRNAs and other regulatory RNAs. Over the past 15 years his lab has contributed to the understanding of the genomics, biogenesis and regulatory targets of these RNAs, as well as the molecular and biological consequences of their actions in animals, plants and fungi.